The objective of the study was to formulate a transdermal product containing Nicorandil as a model drug, because it has been first drug of choice to treat angina and hypertension. A further objective was to reduce its side effects. The transdermal product was prepared using various synthetic and natural gelling agents such as Carbopol 934p, Carbopol 974p, HPMC K15M and HPMC K100M. Various penetration enhancers were incorporated to enhance the diffusion across the rat skin. A further objective was to formulate organogels and minimize the concentration of penetration enhancer to 50% of the concentration used in gels and yet to achieve the maximum drug release. The prepared formulations were evaluated for their physical appearance, viscosity, spreadability, drug content and freeze thaw cycle. Based on in vitro studies across rat skin and human cadaver skin it was concluded that Nicrorandil transdermal organogel formulation using HPMC K100M with 2% w/w Transcutol-P shows increase in cumulative diffusion of Nicorandil amongst all other formulations.
Keywords: Transdermal, nicorandil, carbopol, organogel.
P2 Receptors in Renal Autoregulation
Current Vascular Pharmacology Candidate Genes in the Pharmacogenomics of Antihypertensive Treatment - A Review and Future Aspects
Current Pharmacogenomics Patient Engagement in Randomized Controlled Tai Chi Clinical Trials among the Chronically Ill
Reviews on Recent Clinical Trials Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Impact of Red Wine Consumption on Cardiovascular Health
Current Medicinal Chemistry Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Current Hypertension Reviews Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology Aliskiren: A Novel Renin Inhibitor for Hypertension
Current Drug Therapy Brain MRI, Apoliprotein E Genotype, and Plasma Homocysteine in American Indian Alzheimer Disease Patients and Indian Controls
Current Alzheimer Research Primary Hyperaldosteronism in the Hypertensive Disease
Current Hypertension Reviews Pulmonary Hypertension: Role of Combination Therapy
Current Vascular Pharmacology The Role of PDE5-Inhibitors in Cardiopulmonary Disorders: From Basic Evidence to Clinical Development
Current Medicinal Chemistry Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease
Current Vascular Pharmacology Cardiotonic Steroids, Hypertension and Cardiovascular Disease
Current Hypertension Reviews Difference in the Influence of the Lipid Profile as a Coronary Risk Factor in Patients with and Without Diabetes Mellitus
Vascular Disease Prevention Clinical Value of Measuring the Renin/Aldosterone Levels: Optimising the Management of Uncontrolled/Resistant Hypertension
Current Vascular Pharmacology New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Identification of Defective CD36 as a Quantitative Trait Locus for Cardiovascular Risk Factor Clustering in the Spontaneously Hypertensive Rat